CAR T-cell therapy

Posted on by Leakey
  1. CAR T-cell therapy is approved by FDA to treat some forms of aggressive blood cancer (e.g., refractory non-Hodgkin lymphoma, relapsed or refractory acute lymphoblastic leukemia) in patients up to age 25. How does this therapy work? Cite outcomes from clinical trials, listed in peer- reviewed publications. What are the limitations of this cellular engineering approach? What are some side-effects and how could they be overcome in future? How can we adapt that platform to treat another such condition in the humans, say solid tumors?

This question has been answered.

Get Answer